Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg-Strauss Syndrome, is a rare autoimmune disorder characterized by necrotizing vasculitis of small-to medium-sized blood ...

(StatePoint) An estimated 5,000 people in the United States are living with Eosinophilic Granulomatosis with Polyangiitis (EGPA), a rare form of vasculitis that causes inflammation or swelling in the ...

Eosinophilic granulomatosis with polyangiitis (EGPA; previously known as Churg-Strauss syndrome) is typically characterized by asthma, blood and tissue eosinophilia, and small-vessel vasculitis. 1 ...

The Philippines's "Queen of All Media" is currently in the United States as she undergoes treatment for her autoimmune disorders. She previously shared that she was diagnosed with chronic spontaneous ...

First head-to-head trial of biologics in EGPA, comparing a single monthly injection of Fasenra to three injections per month of mepolizumab Positive high-level results from the MANDARA Phase III trial ...

Patients with eosinophilic granulomatosis with polyangiitis who received 2 years of treatment with the interleukin-5 ...

AstraZeneca’s (AZ) Fasenra (benralizumab) has been approved by the US Food and Drug Administration (FDA) to treat adults with eosinophilic granulomatosis with polyangiitis (EGPA), a rare ...

PARAMUS, N.J., April 21, 2025 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma) a subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku), announced today that the U.S. Food & Drug Administration (FDA) ...

AstraZeneca’s Fasenra (benralizumab) has been approved by the European Commission (EC) to treat eosinophilic granulomatosis with polyangiitis (EGPA), a rare immune-mediated inflammatory disease that ...

Dr. Michael Wechsler, Professor of Medicine and Director of The Asthma Institute at National Jewish Health, and International Coordinating Investigator of the MANDARA trial said: “Patients with EGPA ...

First head-to-head trial of biologics in EGPA, comparing a single monthly injection of FASENRA to three injections per month of mepolizumab WILMINGTON, Del., September 11, 2023--(BUSINESS ...